Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma.

Antibodies (Basel) · 2025 · PMC11939718 · PMID 40136475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

There was a clear trend between CLDN18.2 expression and anti-tumor efficacy for this cohort.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.